-
ESMO Flash Report: How to choose newly-treated EGFR-mutant non-squamous NSCLC patients
Time of Update: 2021-09-30
Trastuzumab+nivolumab+FOLFOX further improves the overall survival rate of patients with esophageal gastric adenocarcinoma!
——LBA45—Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma (EGA) – results of the randomized phase 2 INTEGA trial (AIO STO 0217).
-
Prostate Cancer PD: Preoperative PSMA-PET/CT of prostate cancer can be used as a predictor of persistent and early recurrence of postoperative biochemistry
Time of Update: 2021-09-18
Univariate logistic regression of BCP and BCR predictors Univariate logistic regression of BCP and BCR predictorsIn summary, preoperative PSMA-PET/CT is an important tool for predicting the risk of BCP and early BCR after surgery, and can provide valuable information for patients treated with RARP+ePLND .
-
Good news I Zejing Pharmaceuticals, Donafenib Tosylate Tablets, Successfully Phase III Clinical Trial in the Treatment of Iodine-Refractory Differentiated Thyroid Cancer
Time of Update: 2021-08-28
Recently, Zejing Pharmaceutical Donafinil Tosylate Tablets (hereinafter referred to as "donafinil") in the treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is a multi-center, random, double The blinded, placebo-controlled Phase III clinical trial (code: ZGDD3) carried out a predetermined interim analysis, and the Independent Data Monitoring Committee (IDMC) reviewed the results and determined that the effectiveness and safety results were in line with expectations .
-
Innovative treatments for prostate cancer
Time of Update: 2021-08-07
The results showed that in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), compared with standard care (SOC), 177Lu-PSMA-617 combined with SOC significantly improved overall survival (OS) and radiology Progression-free survival (rPFS) .
-
Non-invasive liquid biopsy helps cancer diagnosis obtain CE certification
Time of Update: 2021-07-19
TruBlood is a blood-based non-invasive test method used to diagnose and evaluate suspected cancer cases for which a biopsy is recommended .
-
ASCO specific pancreatic cancer patients have a response rate of 42%, and initial clinical results of innovative bispecific antibody therapy are positive
Time of Update: 2021-06-17
In the treatment of pancreatic cancer patients with NRG1 fusion-positive, zenocutuzumab achieved a confirmed total remission rate of 42% (5/12) .
Zenocutuzumab is a bispecific antibody that targets both HER2 and HER3 receptors, designed to accurately treat patients with solid tumors that are positive for NRG1 fusion .
-
Science Advances | The method is simpler
Time of Update: 2021-05-21
On May 12, 2021, Liu Jinyao's team from Shanghai Jiaotong University published a research paper titled "Mucosal immunity–mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer's patches" online in Science Advances.
-
Nature sub-journal: Study finds that the body's magical brown fat can prevent a variety
Time of Update: 2021-03-09
Obesity is known to be a major cause of metabolic and cardiovascular disease. In addition to the white fats that store calories that can lead to obesity, there is another magical brown fat (BAT) tha
-
The treatment of non-small cell lung cancer energizer KRAS inhibitors reached 80.6% disease control rate
Time of Update: 2021-03-03
Today, Amgen announced the latest results from a critical Phase 2 clinical trial in patients with advanced non-small cell lung cancer (NSCLC) who studied the KRAS G12C inhibitor sotorasib (AMG 510).
-
FDA accelerates approval of innovative PI3K inhibitors to treat lymphoma
Time of Update: 2021-02-24
in patients with marginal lymphoma (MZL), Ukoniq achieved an objective remission rate (ORR) of 49%, including a full remission rate of 16%, and the medium remission duration (DOR) had not yet been achieved.
-
Breast cancer targeted treatment! Novarce Kisqali performs in patients with incurable visceral metastasis HR-/HER2-advanced breast cancer
Time of Update: 2021-02-17
The data showed that in patients with advanced breast cancer 2 negative (HR-/HER2-) pre-menopathic, peri-menopathic, post-menotinal hormone-positive, human skin growth factor(HR-/HER2-) advanced breast cancer, Kisqali combined endocrine therapy significantly extended progression-free survival (PFS) compared to endocrine alone treatment, regardless of whether the patient had visceral metastasis.
-
Nat Genet: The malfunction of the genome structure may induce the occurrence of B cell malignant tumors
Time of Update: 2021-02-15
4, 2021 // -- In a recent study published in the international journal Nature Genetics, scientists from Columbia University's Irvine Medical Center and others found that errors in chromosome arrangement in B cells that produce antibodies appear to play a key role in the development of B-cell-related blood cancers.
-
Clin Cancer Res: Quantified tumor mutation load based on ctDNA is a good predictor of whether metastasis NSCLC patients will benefit from immunotherapy
Time of Update: 2021-02-12
with the new bTMB algorithm and the best bTMB threshold (≥20 mut/Mb), high bTMB is a predictive indicator that metastasis NSCLC patients benefit from durvalumab-tremelimumab or chemotherapy.
-
New clinical standard for RAF melanoma! The new targeted combination therapy Braftovi and Mektovi has been approved by NICE UK
Time of Update: 2021-02-09
France's Pierre Fabre recently announced that the UK's National Institute for Health and Clinical Optimization (NICE) has issued guidelines recommending a combination of Braftovi (binimetinib, a MEK inhibitor) and Mektovi (a BRAf inhibitor) for the treatment of adult patients with non-removable melanoma who have been tested for the BRAF V600 mutation.
-
Regenerant Bioanti-TIGIT Monoantigen JS006 Injection was approved for clinical trials
Time of Update: 2021-01-29
On January 27, Junshi Bio announced that the anti-TIGIT monoantigen JS006 injection was approved for clinical trials of the drug.
preclinical results show that JS006 can specificly block TIGIT-PVR inhibition path, stimulate the activity of lethal immune cells, and secrete tumor killer factors.
